Shots:

• The company reported the 1yrs. results from the P-III KESTREL & KITE studies assessing Beovu (6mg) vs aflibercept (2mg) in 926 patients with DME across 36 countries
• Results: met its 1EPs i.e. non-inferiority in mean change BCVA from baseline @48wks.- patients treated with Beovu (6mg) experienced fluid (IRF/SRF) resolution and achieved CSFT levels below 280 μm @32 & 52 wks.- was well-tolerated safety in both studies
• Novartis is committed to bring Beovu (6mg) to DME patients and will submit the data from both trails to global health authorities in H1’21 while the company anticipates 2yrs. results in late 2021

  Ref: PRnewswire | Image: Novartis